The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.

Jie ChenXiaona ChangXinyi LiJiaying LiuNa WangYing WuLiduan ZhengXiu Nie

Published in: Cancer medicine (2023)

Receiving targeted therapy had a heterogeneous impact on the prognosis of CRC patients harboring different TP53 mutations. These results provide promising value for future personalized treatment and precision medicine.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
current status
patient reported outcomes
smoking cessation